Neuroradiology · 2023 · 10 citations · 34 references
MedicineOncologyRadiologyDiagnostic ImagingDiagnostic RadiologyUltrasonographyMagnetic Resonance ImagingPost-therapy ImagingProton TherapyRadiation TherapyRadiotherapy For Skin CancerUltrasound In OncologyDiffusion-weighted ContrastFunctional ImagingPerfusion-weighted ImagingPosttherapy ImagingPretherapy ImagingTime-intensity CurvesTumor Diffusion ImagingTumor Perfusion Analysis
Abstract Purpose MRI is increasingly used in the diagnosis and therapy planning of uveal melanoma (UM). In this prospective cohort study, we assessed the radiological characteristics, in terms of anatomical and functional imaging, of UM after ruthenium-106 plaque brachytherapy or proton beam therapy (PBT) and compared them to conventional ultrasound. Methods Twenty-six UM patients were evaluated before and 3, 6 and 12 months after brachytherapy ( n = 13) or PBT ( n = 13). Tumour prominences were compared between ultrasound and MRI. On diffusion-weighted imaging, the apparent diffusion value (ADC), and on perfusion-weighted imaging (PWI), the time-intensity curves (TIC), relative peak intensity and outflow percentages were determined. Values were compared between treatments and with baseline. Results Pre-treatment prominences were comparable between MRI and ultrasound (mean absolute difference 0.51 mm, p = 0.46), but larger differences were observed post-treatment (e.g. 3 months: 0.9 mm ( p = 0.02)). Pre-treatment PWI metrics were comparable between treatment groups. After treatment, brachytherapy patients showed favourable changes on PWI (e.g. 67% outflow reduction at 3 months, p < 0.01). After PBT, significant perfusion changes were observed at a later timepoint (e.g. 38% outflow reduction at 6 months, p = 0.01). No consistent ADC changes were observed after either treatment, e.g. a 0.11 × 10 −3 mm 2 /s increase 12 months after treatment ( p = 0.15). Conclusion MR-based follow-up is valuable for PBT-treated patients as favourable perfusion changes, including a reduction in outflow, can be detected before a reduction in size is apparent on ultrasound. For brachytherapy, a follow-up MRI is of less value as already 3 months post-treatment a significant size reduction can be measured on ultrasound.
34
K. C. Ossoinig · International Ophthalmology Clinics · 1979 · 403 citations
The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma
Lee M. Jampol, Claudia S. Moy, Timothy G. Murray et al. · Ophthalmology · 2002 · 367 citations
Medicine, Oncology, Ophthalmology +16
Daniel A. Hamstra, Craig J. Galbán, Charles R. Meyer et al. · Journal of Clinical Oncology · 2008 · 283 citations · Full text
Guidelines for imaging retinoblastoma: imaging principles and MRI standardization
Pim de Graaf, Sophia Göricke, Firazia Rodjan et al. · Pediatric Radiology · 2011 · 226 citations · Full text
Medicine, Ophthalmology, Radiology +17